Epileptic Disorders
MENUMega-dose phenobarbital therapy for super-refractory status epilepticus Volume 17, numéro 4, December 2015
Auteurs
Aims
Departments of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute,
1 Seoul National University Hospital,
2 Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea
* Correspondence: Sang Kun Lee
Department of Neurology,
Seoul National University Hospital,
101 Daehang-ro, Chongro-gu,
Seoul 110-744, South Korea
a Authors contributed equally.
- Mots-clés : super-refractory status epilepticus, mega-dose phenobarbital, management, outcome
- DOI : 10.1684/epd.2015.0778
- Page(s) : 444-52
- Année de parution : 2015
To evaluate the efficacy and safety of mega-dose phenobarbital (MDPB; enteral or parenteral phenobarbital >10 mg/kg/day) for treating super-refractory status epilepticus (SRSE; continuous or recurrent status epilepticus for ≥24 hours after the onset of continuous anaesthetic treatment) in adult patients.